Summary of OREXIGEN THERAPEUTICS, INC.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On November 9, 2008, Gary Tollefson, M.D., Ph.D., President and Chief Executive Officer of Orexigen Therapeutics, Inc. (the "Company"), commenced a leave of absence from the Company, effective immediately. Dr. Tollefson is expected to remain on the Company's Board of Directors (the "Board") during this leave of absence. The Board intends to retain an executive search firm to assist it in recruiting for this position.

(c) On November 9, 2008, the Board appointed Eckard Weber, M.D. to the position of Executive Chairman of the Board and interim President and Chief Executive Officer, effective immediately.

Dr. Weber is one of the Company's co-founders and has served as a member of the Board since the Company's inception in September 2002, and as Chairman of the Board since March 2004. From September 2002 to September 2003 and from January 2005 to April 2005, Dr. Weber served as the Company's President and Chief Executive Officer. Dr. Weber is a partner at Domain Associates, L.L.C. ("Domain"), a private venture capital management firm focused on life sciences, a position he has held since 2001. Dr. Weber has been a founding Chief Executive Officer and board member of multiple biopharmaceutical companies in the Domain portfolio including Acea Pharmaceuticals Inc., Ascenta Therapeutics, Inc., Calixa Therapeutics, Inc., Cytovia, Inc., Domain AntiBacterial Acquisition Corporation, NovaCardia, Inc., Novacea, Inc., Novalar Pharmaceuticals, Inc., Ocera Therapeutics Inc., Sonexa Therapeutics Inc., Syndax Pharmaceuticals Inc., Tobira Therapeutics, Inc. and Tragara Pharmaceuticals, Inc. Dr. Weber currently serves as interim Chief Executive Officer of Calixa Therapeutics and Sonexa Therapeutics, two seed stage biopharmaceutical companies. He is Chairman of the Board at Ascenta Therapeutics, Inc., Calixa Therapeutics, Ocera Therapeutics Inc., Sequel Pharmaceuticals, Inc., Syndax Pharmaceuticals and Tobira Therapeutics, Inc. Dr. Weber was Chairman of the Board of Peninsula Pharmaceuticals, Inc. until the company was sold to Johnson & Johnson in 2005, chairman of Cerexa Inc. until the company was sold to Forest Laboratories, Inc. in January 2007, chairman of NovaCardia, Inc. until the company was sold to Merck in September 2007, and a board member of Conforma Therapeutics Corporation and Cabrellis Pharmaceuticals Corporation until they were sold to Biogen-IDEC, Inc. and Pharmion Corporation, respectively. In addition, Dr. Weber is a board member of BioVascular, Inc. and DiObex, Inc. Until 1995, Dr. Weber was a tenured Professor of Pharmacology at the University of California at Irvine. Dr. Weber holds a B.S. from Kolping College in Germany and an M.D. from the University of Ulm Medical School in Germany.

The Company issued a press release on November 10, 2008 announcing Dr. Tollefson's leave of absence and Dr. Weber's appointment, a copy of which is attached hereto as Exhibit 99.1.